Liminatus Pharma (LIMN) Research & Development (2024 - 2026)

Liminatus Pharma (LIMN) posted Research & Development of $400000.0 for Q1 2026, up 12.02% sequentially from $357066.0 in Q3 2024.

Liminatus Pharma (LIMN) Research & Development (2024 - 2026) Analysis & Trends

Liminatus Pharma has reported Research & Development for 2 years, with the latest figure at $400000.0 in Q1 2026.

Quarterly Research & Development changed N/A year-over-year to $400000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $757066.0 (down 29.33% YoY) and the FY2024 annual result came in at $2.7 million, changed N/A from the prior year.
Research & Development climbed to $400000.0 in Q1 2026 per LIMN's latest filing, from $357066.0 in the prior quarter.
Over five years, Research & Development peaked at $714134.0 in Q2 2024 and troughed at $357066.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	R&D (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	993.80 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.63 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	651.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	612.28 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	413.13 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	210.03 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	97.90 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-588.31 Mn
10	Liminatus Pharma	5.46 Mn	5.46 Mn	-	600,000.00

Download Data